DreamCIS

DreamCIS EBIT Margin

The EBIT Margin (Operating Margin) of DreamCIS (223250.KQ) as of Oct 29, 2026 is 7.86 %. In the previous year, EBIT Margin (Operating Margin) was 8.62 % — a change of -8.83% (lower).

EBIT Margin

7.86 %

YoY

-8.83%

Last updated:

EBIT Margin (Operating Margin) of DreamCIS is 2025 7.86 % . EBIT Margin (Operating Margin) of DreamCIS was 2024 8.62 % . It decreases by -8.83% lower compared to the previous year.

DreamCIS's operating (EBIT) margin stands at 7.9%, down from 13.8% several years earlier.

The DreamCIS EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
18.61 KRW
Jan 1, 2019
19.61 KRW
Jan 1, 2020
20.41 KRW
Jan 1, 2021
13.85 KRW
Jan 1, 2022
14.75 KRW
Jan 1, 2023
3.32 KRW
Jan 1, 2024
8.62 KRW
Jan 1, 2025
7.86 KRW
The DreamCIS EBIT Margin history
YEAREBIT MarginYoY
7.86 %-8.83%
8.62 %+159.82%
3.32 %-77.49%
14.75 %+6.49%
13.85 %-32.15%
20.41 %+4.07%
19.61 %+5.37%
18.61 %-382.40%
-6.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DreamCIS Stock analysis

What does DreamCIS do? DreamCIS Inc. is a company based in Seoul, South Korea, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 22, 2020, with its stock listed under the ticker 223250.KQ and ISIN KR7223250002. DreamCIS Inc. provides clinical online information and consultation services, focusing on regulatory post-marketing surveillance (rPMS), clinical trials, and non-interventional studies (NIS). The company serves both domestic and international markets, offering its services to clients seeking support in clinical research and regulatory compliance. Its headquarters are located in Seoul, South Korea. The company's website is http://www.dreamcis.com/, which serves as a primary source for further information about its services and operations. DreamCIS Inc. does not provide detailed information about its founding year, specific leadership, or financial figures beyond its IPO date, and no acquisitions or additional product names are mentioned in the provided data. The company's services are primarily aimed at facilitating clinical research and ensuring adherence to regulatory standards in the life sciences sector. DreamCIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DreamCIS stock

EBIT Margin (Operating Margin) of DreamCIS is 7.86 % in 2025.

EBIT Margin (Operating Margin) of DreamCIS changed from 8.62 % to 7.86 %, representing a -8.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) DreamCIS since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s DreamCIS with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DreamCIS

All Key Metrics — DreamCIS